Swiss-Dutch Pharma Biz Raises €80M For Cancer Drug Work
iOnctura BV has raised €80 million ($85.5 million) in a new round of financing, which the Swiss-Dutch biopharmaceutical company will use to continue developing two anti-cancer drugs....To view the full article, register now.
Already a subscriber? Click here to view full article